-
2
-
-
0029890251
-
Molecular basis of hypoxia-induced erythropoietin expression
-
Wang GL, Semenza GL. Molecular basis of hypoxia-induced erythropoietin expression. Curr Opin Hematol. 1996;3:156-162. (Pubitemid 26178055)
-
(1996)
Current Opinion in Hematology
, vol.3
, Issue.2
, pp. 156-162
-
-
Wang, G.L.1
Semenza, G.L.2
-
4
-
-
84859432838
-
-
Neuss, Germany: JANSSEN-CILAG GmbH Germany
-
Erypo/Erypo Product information. Neuss, Germany: JANSSEN-CILAG GmbH Germany; 2002.
-
(2002)
Erypo/Erypo Product Information
-
-
-
5
-
-
0035163281
-
Identification of patients and risk factors in chronic kidney disease - Evaluating risk factors and therapeutic strategies
-
Levin A. Identifcation of patients and risk factors in chronic kidney disease-evaluating risk factors and therapeutic strategies. Nephrol Dial Transplant. 2001;16:57-60. (Pubitemid 33062125)
-
(2001)
Nephrology Dialysis Transplantation
, vol.16
, Issue.SUPPL. 7
, pp. 57-60
-
-
Levin, A.1
-
6
-
-
84859434984
-
Anemia management in patients with chronic renal disease: Current recommendations
-
Tarif N. Anemia management in patients with chronic renal disease: current recommendations. Saudi J Kidney Dis Transpl. 2002;13:331-335.
-
(2002)
Saudi J Kidney Dis Transpl
, vol.13
, pp. 331-335
-
-
Tarif, N.1
-
7
-
-
0027010484
-
Treatment of renal anemia with recombinant human erythropoietin
-
Macdougall IC. Treatment of renal anemia with recombinant human erythropoietin. Curr Opin Nephrol Hypertens. 1992;1:210-219.
-
(1992)
Curr Opin Nephrol Hypertens
, vol.1
, pp. 210-219
-
-
MacDougall, I.C.1
-
8
-
-
26944435921
-
Quality of life in patients on dialysis: Benefts of maintaining a hemoglobin of 11 to 12 g/dl
-
Gregory N. Quality of life in patients on dialysis: benefts of maintaining a hemoglobin of 11 to 12 g/dL. Nephrol Nurs J. 2005;32:307-310.
-
(2005)
Nephrol Nurs J
, vol.32
, pp. 307-310
-
-
Gregory, N.1
-
9
-
-
0030002368
-
Long-term impact of recombinant human erythropoietin on transfusion support in patients with chronic renal failure
-
Popovsky MA, Ransil BJ. Long-term impact of recombinant human erythropoietin on transfusion support in patients with chronic renal failure. Immunohematol. 1996;12:1-3. (Pubitemid 26102951)
-
(1996)
Immunohematology
, vol.12
, Issue.1
, pp. 1-3
-
-
Popovsky, M.A.1
Ransil, B.J.2
-
10
-
-
0034027195
-
Morbidity and mortality reduction associated with the use of erythropoietin
-
Tsakiris D. Morbidity and mortality reduction associated with the use of erythropoietin. Nephron. 2000;85 (suppl. 1):2-8. (Pubitemid 30192921)
-
(2000)
Nephron
, vol.85
, Issue.SUPPL. 1
, pp. 2-8
-
-
Tsakiris, D.1
-
11
-
-
0032991310
-
Hematocrit levels and hospitalization risks in hemodialysis patients
-
Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol. 1999;10:1309-1316. (Pubitemid 29246997)
-
(1999)
Journal of the American Society of Nephrology
, vol.10
, Issue.6
, pp. 1309-1316
-
-
Xia, H.1
Ebben, J.2
Ma, J.Z.3
Collins, A.J.4
-
14
-
-
41149131276
-
Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment
-
DOI 10.1185/030079908X273264
-
Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R. The epoetin zeta study group. Comparison of the therapeutic Effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin. 2008;24: 625-637. (Pubitemid 351428973)
-
(2008)
Current Medical Research and Opinion
, vol.24
, Issue.3
, pp. 625-637
-
-
Wizemann, V.1
Rutkowski, B.2
Baldamus, C.3
Scigalla, P.4
Koytchev, R.5
-
15
-
-
44349139462
-
Comparison of the therapeutic effects of epoetin zeta and epoetin alfa in the correction of renal anaemia
-
DOI 10.1185/030079908X297402
-
Krivoshiev S, Todorov V, Manitius J, Czekalski S, Scigalla P, Koytchev R. Epoetin Zeta Study Group. Comparison of the therapeutic Effects of epoetin zeta and epoetin alfa in the correction of renal anemia. Curr Med Res Opin. 2008;24:1407-1415. (Pubitemid 351741574)
-
(2008)
Current Medical Research and Opinion
, vol.24
, Issue.5
, pp. 1407-1415
-
-
Krivoshiev, S.1
Todorov, V.V.2
Manitius, J.3
Czekalski, S.4
Scigalla, P.5
Koytchev, R.6
-
18
-
-
84859426332
-
-
Step 5, Consolidated Guideline from 01.05.1996. Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95). Woden, Australia: TGA Accessed September 2, 2008
-
ICH Topic E 6. Guideline for Good Clinical Practice. Step 5, Consolidated Guideline from 01.05.1996. Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95). Woden, Australia: TGA; 2000. Available at: www.tga.gov.au/docs/pdf/euguide/ich/ich13595.pdf. Accessed September 2, 2008.
-
(2000)
ICH Topic e 6. Guideline for Good Clinical Practice
-
-
-
19
-
-
4344581912
-
Revised european best practice guidelines for the management of anaemia in patients with chronic renal failure
-
Locatelli F, Aljama P, Bárány P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 2004;19(suppl. 2):1-47.
-
(2004)
Nephrol Dial Transplant.
, vol.19
, Issue.SUPPL. 2
, pp. 1-47
-
-
Locatelli, F.1
Aljama, P.2
Bárány, P.3
-
21
-
-
0345059073
-
The detection of anti-erythropoietin antibodies in human serum and plasma: Part I. Validation of the protocol for a radioimmunoprecipitation assay
-
DOI 10.1016/j.jim.2003.09.003
-
Tacey R, Greyway A, Smiell J, et al. The detection of anti-erythropoietin antibodies in human serum and plasma. Part I. Validation of the protocol for a radioimmunoprecipitation assay. J Immunol Meth. 2003;283:317-329. (Pubitemid 37501079)
-
(2003)
Journal of Immunological Methods
, vol.283
, Issue.1-2
, pp. 317-329
-
-
Tacey, R.1
Greway, A.2
Smiell, J.3
Power, D.4
Kromminga, A.5
Daha, M.6
Casadevall, N.7
Kelley, M.8
-
22
-
-
4043133064
-
Epoetin-induced autoimmune pure red cell aplasia
-
Casadevall N. Epoetin-induced autoimmune pure red cell aplasia. Hematol J. 2004;5(suppl. 3):104-109.
-
(2004)
Hematol J.
, vol.5
, Issue.SUPPL. 3
, pp. 104-109
-
-
Casadevall, N.1
-
23
-
-
9644276661
-
Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia
-
DOI 10.1111/j.1600-0609.2004.00348.x
-
Casadevall N, Cournoyer D, Marsh J, et al. Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia. Eur J Haematol. 2004;73:389-396. (Pubitemid 39571711)
-
(2004)
European Journal of Haematology
, vol.73
, Issue.6
, pp. 389-396
-
-
Casadevall, N.1
Cournoyer, D.2
Marsh, J.3
Messner, H.4
Pallister, C.5
Parker-Williams, J.6
Rossert, J.7
-
24
-
-
0032572915
-
Erythropoietin for end-stage renal disease
-
DOI 10.1056/NEJM199808273390910
-
Adamson JW, Eschbach JW. Erythropoietin for end-stage renal disease. N Engl J Med. 1998;339;625-627. (Pubitemid 28385662)
-
(1998)
New England Journal of Medicine
, vol.339
, Issue.9
, pp. 625-627
-
-
Adamson, J.W.1
Eschbach, J.W.2
-
25
-
-
84859423269
-
-
Toronto, ON: Janssen-Ortho CA Inc.
-
Eprex Product information. Toronto, ON: Janssen-Ortho CA Inc.; 2006.
-
(2006)
Eprex Product Information
-
-
-
26
-
-
84859422377
-
NeoRecormon Product information
-
Hertfordshire: Roche Registration Ltd.
-
NeoRecormon Product information. Welwyn Garden City, Hertfordshire: Roche Registration Ltd.; 2002.
-
(2002)
Welwyn Garden City
-
-
-
27
-
-
0141786792
-
Hemoglobin variability in epoetin-treated hemodialysis patients
-
DOI 10.1046/j.1523-1755.2003.00229.x
-
Berns JS, Elzein H, Lynn RI, Fishbane S, Meisels IS, Deoreo PB. Hemoglobin variability in epoetin-treated hemodialysis patients. Kidney Int. 2003,64:1514-1521. (Pubitemid 37153820)
-
(2003)
Kidney International
, vol.64
, Issue.4
, pp. 1514-1521
-
-
Berns, J.S.1
Elzein, H.2
Lynn, R.I.3
Fishbane, S.4
Meisels, I.S.5
Deoreo, P.B.6
-
28
-
-
0024790160
-
Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial
-
Eschbach J W, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med. 1989;111:992-1000. (Pubitemid 20034923)
-
(1989)
Annals of Internal Medicine
, vol.111
, Issue.12
, pp. 992-1000
-
-
Eschbach, J.W.1
Abdulhadi, M.H.2
Browne, J.K.3
Delano, B.G.4
Downing, M.R.5
Egrie, J.C.6
Evans, R.W.7
Friedman, E.A.8
Graber, S.E.9
Haley, N.R.10
Korbet, S.11
Krantz, S.B.12
Lundin, A.P.13
Nissenson, A.R.14
Ogden, D.A.15
Paganini, E.P.16
Rader, B.17
Rutsky, E.A.18
Stivelman, J.19
-
29
-
-
0026036493
-
Side effects during recombinant human erythropoietin therapy in 2000 ESRD patients
-
Samtleben W, Ehmer B, Lutz-Knochenhauer I, Hagmann C, Scigalla P, Gurland HJ. Side Effects during recombinant human erythropoietin therapy in 2000 ESRD patients. Contrib Nephrol. 1991;88:107-116.
-
(1991)
Contrib Nephrol
, vol.88
, pp. 107-116
-
-
Samtleben, W.1
Ehmer, B.2
Lutz-Knochenhauer, I.3
Hagmann, C.4
Scigalla, P.5
Gurland, H.J.6
|